Community protocol
Third-party5-Amino-1MQ 10mg
- 01Reconstitution solution
- 1 mL
- 02Dose
- 1 mg
- 03Syringe units
- 10 units
- 04Frequency
- 7x/week
- 05Cycle length
- 90 days
- 06Bacteriostatic water
- 1 mL
- 07Bottle size
- 10 mg
- 08Bottles needed
- 9
5-Amino-1MQ
A small molecule, not a peptide, sold alongside them. It blocks the enzyme NNMT in fat tissue. The data is mouse-only — there are no human trials.
Overview
Fat cells contain an enzyme called NNMT that consumes NAD building blocks and helps the cell store energy rather than burn it. 5-Amino-1MQ blocks that enzyme. In obese mice, blocking it raised NAD levels inside fat tissue, shrank fat cells and reduced body weight without changing how much the animals ate. Nothing equivalent has been run in people, and it is worth being clear that this is a quinolinium salt, not a peptide at all.
Nicotinamide N-methyltransferase (NNMT) catalyses methylation of nicotinamide to 1-methylnicotinamide, consuming S-adenosylmethionine and diverting nicotinamide away from NAD+ salvage. 5-Amino-1-methylquinolinium is a cell-permeant bisubstrate-competitive NNMT inhibitor with reported sub-micromolar potency. In diet-induced obese mice, oral dosing increased adipose NAD+ and SAM, reduced adipocyte size and produced weight loss without altered food intake. Selectivity across the broader methyltransferase family, oral bioavailability in humans, and any chronic toxicology package are not established in the peer-reviewed record.
Research areas
ObesityNAD metabolismAdipose biology
Community-specified data
Community dosage information
Community protocol
Third-party5-Amino-1MQ 50mg
- 01Reconstitution solution
- 2.5 mL
- 02Dose
- 1 mg
- 03Syringe units
- 5 units
- 04Frequency
- 7x/week
- 05Cycle length
- 90 days
- 06Bacteriostatic water
- 2.5 mL
- 07Bottle size
- 50 mg
- 08Bottles needed
- 2
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| Oral 5-amino-1MQ in diet-induced obese mice, dosed daily for 11 daysMouse study. No human equivalent dose has been established by any route. | Neelakantan et al., Biochemical Pharmacology 2018 |
Trial status
No registered human clinical trials. All efficacy data is preclinical, largely from one research group.
Reported safety signals
- No human safety data of any kind has been published.
- NNMT is expressed in liver and other tissues, so systemic inhibition is not confined to fat.
- Marketed products are unregulated; purity and actual content are not independently verified.
Common questions
Is 5-Amino-1MQ a peptide?
No. It is a small-molecule quinolinium salt. It is listed alongside peptides because it is sold through the same channels, not because it shares any chemistry with them.
Has it been tested in humans?
Not in any registered clinical trial. Every weight-loss result you will see quoted comes from mice, and mouse obesity models translate poorly to human weight management.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →